{
    "organizations": [],
    "uuid": "36c1db2971ca0e81dd85304db14740b6d452f1b3",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-pharma-mar-licenses-marine-derived/brief-pharma-mar-licenses-marine-derived-payloads-to-seattle-genetics-idUSFWN1Q405B",
    "ord_in_thread": 0,
    "title": "BRIEF-Pharma Mar Licenses Marine-Derived Payloads To Seattle Genetics",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 14 (Reuters) - PHARMA MAR SA:\n* LICENSES FULLY SYNTHETIC MARINE-DERIVED PAYLOADS TO SEATTLE GENETICS FOR USE IN DRUG CONJUGATES\n* SAYS WILL RECEIVE UPFRONT PAYMENT OF $5.0 MILLION ON SIGNING, FOLLOWED BY DEVELOPMENT MILESTONES IF A PRODUCT ENTERS CLINICAL DEVELOPMENT CONDUCTED BY SEATTLE GENETICS\n* IS ELIGIBLE FOR POTENTIAL APPROVAL AND SALES MILESTONES, ROYALTIES, ONCE PRODUCT GETS REGULATORY APPROVAL AND IS COMMERCIALIZED Source text for Eikon:\nFurther company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-14T15:31:00.000+02:00",
    "crawled": "2018-02-15T20:26:38.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "pharma",
        "mar",
        "sa",
        "license",
        "fully",
        "synthetic",
        "payload",
        "seattle",
        "genetics",
        "use",
        "drug",
        "conjugate",
        "say",
        "receive",
        "upfront",
        "payment",
        "million",
        "signing",
        "followed",
        "development",
        "milestone",
        "product",
        "enters",
        "clinical",
        "development",
        "conducted",
        "seattle",
        "genetics",
        "eligible",
        "potential",
        "approval",
        "sale",
        "milestone",
        "royalty",
        "product",
        "get",
        "regulatory",
        "approval",
        "commercialized",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}